Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: Comparison with commercial preparations

被引:215
作者
Vogt, Markus [1 ,2 ]
Kunath, Klaus [2 ]
Dressman, Jennifer B. [1 ]
机构
[1] Univ Frankfurt, Dept Pharmaceut Technol, Frankfurt, Germany
[2] Merck KGaA, Global Pharmaceut Dev, Darmstadt, Germany
关键词
biorelevant media; cogrinding; dissolution rate enhancement; fenofibrate; jet milling; micronization; particle size reduction; spray-drying;
D O I
10.1016/j.ejpb.2007.05.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Several techniques were compared for improving the dissolution of fenofibrate, a poorly soluble drug. Particle size reduction was realized by jet milling (micronization; cogrinding with lactose, polyvinylpyrrolidone or sodium lauryl sulphate) and by media milling using a bead mill (nanosizing) with subsequent spray-drying. Solid state characterization by X-ray diffraction and Differential Scanning Calorimetry verified the maintenance of the crystalline state of the drug after dry milling and its conversion to the amorphous state during spray-drying. Micronization of fenofibrate enhanced its dissolution rate in biorelevant media (8.2% in 30 min) compared to crude material (1.3% in 30 min). Coground mixtures of the drug increased the dissolution rate further (up to 20% in 30 min). Supersaturated solutions were generated by nanosizing combined with spray-drying, this process converted fenofibrate to the amorphous state. Fenofibrate drug products commercially available on the German and French markets dissolved similarly to crude or micronized fenofibrate, but significantly slower than the coground or spray-dried fenofibrate mixtures. The results suggest that cogrinding and spray-drying are powerful techniques for the preparation of rapidly dissolving formulations of fenofibrate, and could potentially lead to improvements in the bioavailability of oral fenofibrate products. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:283 / 288
页数:6
相关论文
共 26 条
[1]   Micronised fenofibrate - Review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia [J].
Adkins, JC ;
Faulds, D .
DRUGS, 1997, 54 (04) :615-633
[2]  
Barth H.G., 1984, MODERN METHODS PARTI
[3]   INDOMETHACIN POLYMERIC NANOSUSPENSIONS PREPARED BY MICROFLUIDIZATION [J].
BODMEIER, R ;
CHEN, HG .
JOURNAL OF CONTROLLED RELEASE, 1990, 12 (03) :223-233
[4]   ACCELERATED STABILITY OF AN X-RAY AMORPHOUS FRUSEMIDE-POLYVINYLPYRROLIDONE SOLID DISPERSION [J].
DOHERTY, C ;
YORK, P .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1989, 15 (12) :1969-1987
[5]   In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs [J].
Dressman, JB ;
Reppas, C .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 11 :S73-S80
[6]   INCREASED METASTABLE SOLUBILITY OF MILLED GRISEOFULVIN, DEPENDING ON THE FORMATION OF A DISORDERED SURFACE-STRUCTURE [J].
ELAMIN, AA ;
AHLNECK, C ;
ALDERBORN, G ;
NYSTROM, C .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 111 (02) :159-170
[7]  
GLOMME A, 2005, PHARMACOKINETIC PROF, P259
[8]   Nanosuspensions of poorly soluble drugs -: reproducibility of small scale production [J].
Grau, MJ ;
Kayser, O ;
Müller, RH .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 196 (02) :155-159
[9]   A new formulation of fenofibrate: Suprabioavailable tablets [J].
Guichard, JP ;
Blouquin, P ;
Qing, Y .
CURRENT MEDICAL RESEARCH AND OPINION, 2000, 16 (02) :134-138
[10]   Characteristics and significance of the amorphous state in pharmaceutical systems [J].
Hancock, BC ;
Zograf, G .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (01) :1-12